As of 2024-07-27, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 73.28 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 23.3x | 20.5x |
| Forward P/E multiples | 21.8x - 27.6x | 24.2x |
| Fair Price | (2,614.90) - (2,792.93) | (2,674.84) |
| Upside | -851027.6% - -908959.7% | -870531.4% |
| Date | EV/EBITDA |
| 2024-07-25 | -0.21 |
| 2024-07-24 | -0.21 |
| 2024-07-23 | -0.21 |
| 2024-07-22 | -0.21 |
| 2024-07-19 | -0.21 |
| 2024-07-18 | -0.21 |
| 2024-07-17 | -0.21 |
| 2024-07-16 | -0.21 |
| 2024-07-15 | -0.21 |
| 2024-07-12 | -0.21 |
| 2024-07-11 | -0.21 |
| 2024-07-10 | -0.21 |
| 2024-07-09 | -0.21 |
| 2024-07-08 | -0.21 |
| 2024-07-05 | -0.21 |
| 2024-07-03 | -0.21 |
| 2024-07-02 | -0.21 |
| 2024-07-01 | -0.21 |
| 2024-06-28 | -0.21 |
| 2024-06-27 | -0.21 |
| 2024-06-26 | -0.21 |
| 2024-06-25 | -0.21 |
| 2024-06-24 | -0.21 |
| 2024-06-21 | -0.21 |
| 2024-06-20 | -0.21 |
| 2024-06-18 | -0.21 |
| 2024-06-17 | -0.21 |
| 2024-06-14 | -0.21 |
| 2024-06-13 | -0.21 |
| 2024-06-12 | -0.21 |
| 2024-06-11 | -0.21 |
| 2024-06-10 | -0.21 |
| 2024-06-07 | -0.21 |
| 2024-06-06 | -0.21 |
| 2024-06-05 | -0.21 |
| 2024-06-04 | -0.21 |
| 2024-06-03 | -0.21 |
| 2024-05-31 | -0.21 |
| 2024-05-30 | -0.21 |
| 2024-05-29 | -0.21 |
| 2024-05-28 | -0.21 |
| 2024-05-24 | -0.21 |
| 2024-05-23 | -0.21 |
| 2024-05-22 | -0.21 |
| 2024-05-21 | -0.21 |
| 2024-05-20 | -0.21 |
| 2024-05-17 | -0.21 |
| 2024-05-16 | -0.21 |
| 2024-05-15 | -0.21 |
| 2024-05-14 | -0.21 |